SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-008457
Filing Date
2022-05-12
Accepted
2022-05-12 09:34:54
Documents
72
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q casi-20220331x10q.htm   iXBRL 10-Q 1379893
2 EX-31.1 casi-20220331xex31d1.htm EX-31.1 12623
3 EX-31.2 casi-20220331xex31d2.htm EX-31.2 12457
4 EX-32.1 casi-20220331xex32d1.htm EX-32.1 7171
5 EX-32.2 casi-20220331xex32d2.htm EX-32.2 7226
  Complete submission text file 0001558370-22-008457.txt   6342439

Data Files

Seq Description Document Type Size
6 EX-101.SCH casi-20220331.xsd EX-101.SCH 51565
7 EX-101.CAL casi-20220331_cal.xml EX-101.CAL 55475
8 EX-101.DEF casi-20220331_def.xml EX-101.DEF 166347
9 EX-101.LAB casi-20220331_lab.xml EX-101.LAB 322083
10 EX-101.PRE casi-20220331_pre.xml EX-101.PRE 281672
66 EXTRACTED XBRL INSTANCE DOCUMENT casi-20220331x10q_htm.xml XML 1247024
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-20713 | Film No.: 22916060
SIC: 2836 Biological Products, (No Diagnostic Substances)